Cas:135641-70-2 Methyl 3(5)-(4-chlorophenyl)-1H-pyrazole-4-carboxylate manufacturer & supplier

Chemical Name:Methyl 3(5)-(4-chlorophenyl)-1H-pyrazole-4-carboxylate

CAS.NO:135641-70-2

Synonyms:Methyl 5-(4-chlorophenyl)-1H-pyrazole-4-carboxylate;methyl 5-(4-chlorophenyl)-1H-pyrazole-4-carboxylate

Molecular Formula:C₁₁H₉ClN₂O₂

Molecular Weight:236.65400

HS Code:2933199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:54.98000

Exact Mass:236.03500

LogP:2.51670

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl 5-(4-chlorophenyl)-1H-pyrazole-4-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 5-(4-chlorophenyl)-1H-pyrazole-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 5-(4-chlorophenyl)-1H-pyrazole-4-carboxylate Use and application,methyl 5-(4-chlorophenyl)-1H-pyrazole-4-carboxylate technical grade,usp/ep/jp grade.

Related News: Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.” cis-aquatetracarbonyl(dimethylphenylphosphine)manganese tetrafluoroborate manufacturers Just last week, the CDC updated J&J’s label again to warn of “an increased risk” for GBS, although the agency has maintained that a definitive link hasn’t been established. Europe’s medicines regulator added its own warning on Thursday just ahead of ACIP’s meeting. Isoquinolinium, 1-(4-chlorophenyl)-2-methyl-, iodide suppliers The CDC’s Advisory Committee on Immunization Practices (ACIP) decision on Thursday came after an hours-long discussion over a handful of Guillain-Barré syndrome (GBS) cases reported after J&J’s jab. The independent group of experts were also tasked with reviewing the need for booster shots, specifically for people with compromised immune systems. 1-(4-methoxy-phenyl)-2-[(4-phenylazo-phenylhydrazono)-methyl]-quinolinium vendor & factory According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug.,Just last week, the CDC updated J&J’s label again to warn of “an increased risk” for GBS, although the agency has maintained that a definitive link hasn’t been established. Europe’s medicines regulator added its own warning on Thursday just ahead of ACIP’s meeting.